Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,781 to 4,800 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Treatment vs Placebo: Rate of Death | 1 of 645 1 of 641 | -0.0 points -0.7 to 0.7 | 1,286 | NCT04308668 Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2 |
| Treatment vs Placebo: Rate of Hospitalization | 5 of 645 9 of 641 | -0.6 points -1.9 to 0.6 | 1,286 | NCT04308668 Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2 |
| Rivaroxaban 10 Milligrams (mg) vs Placebo: Number of Participants With Time to First Occurrence of Primary Efficacy Composite Endpoint | 22 of 641 19 of 643 | 0.5 points -1.5 to 2.5 | 1,284 | NCT04508023 A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection |
| Rivaroxaban 10 Milligrams (mg) vs Placebo: Number of Participants Who Were Hospitalized or Dead on Day 35 | 5 of 641 3 of 643 | 0.3 points -0.7 to 1.4 | 1,284 | NCT04508023 A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection |
| Rivaroxaban 10 Milligrams (mg) vs Placebo: deaths from any cause | 2 of 641 2 of 643 | 0.0 points -0.8 to 0.8 | 1,284 | NCT04508023 A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection |
| Intervention Arm (HITSystem 2.1) vs Control Arm (Standard of Care): Viral Suppression | 655 of 703 535 of 581 | 1.1 points -1.8 to 4.1 | 1,284 | NCT04571684 Evaluating HITSystem 2.1 to Improve Viral Suppression in Kenya |
| LHRHa + TAK-700 vs LHRHa + Bicalutamide: deaths from any cause | 251 of 638 274 of 641 | -3.4 points -8.8 to 2.0 | 1,279 | NCT01809691 S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer |
| MEDI3250 vs Placebo: the Incidence of Laboratory-confirmed Influenza Infection (Any Strain) | 169 of 849 118 of 430 | -7.5 points -12.6 to -2.6 | 1,279 | NCT02269475 A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years |
| MEDI3250 vs Placebo: the Incidence of Laboratory-confirmed Influenza Infection (Matched Strain) | 0 of 849 1 of 430 | -0.2 points -1.3 to 0.3 | 1,279 | NCT02269475 A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years |
| Placebo + Letrozole 2.5 mg vs Lapatinib 1500 mg + Letrozole 2.5 mg: deaths from any cause | 23 of 624 18 of 654 | 0.9 points -1.0 to 3.0 | 1,278 | NCT00073528 Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer |
| Placebo + Letrozole 2.5 mg vs Lapatinib 1500 mg + Letrozole 2.5 mg: serious adverse events | 103 of 624 150 of 654 | -6.4 points -10.8 to -2.1 | 1,278 | NCT00073528 Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Clinical Cure at TOC in the CE-TOC Populations | 611 of 641 617 of 637 | -1.5 points -3.8 to 0.6 | 1,278 | NCT03788967 Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) |
| Old Lina vs New Lina: Number of Patients With HbA1c<6.5% Over Time | 139 of 904 74 of 373 | -4.5 points -9.3 to 0.0 | 1,277 | NCT00736099 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM |
| Old Lina vs New Lina: Number of Patients With HbA1c<7.0% Over Time | 382 of 904 172 of 373 | -3.9 points -9.8 to 2.1 | 1,277 | NCT00736099 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM |
| Old Lina vs New Lina: Number of Patients With Lowered HbA1c by at Least 0.5% Over Time | 155 of 904 175 of 373 | -29.8 points -35.3 to -24.1 | 1,277 | NCT00736099 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM |
| Arm C - Fluticasone vs Arm C - Placebo: Number of Participants With Hospitalization or Death | 3 of 656 3 of 621 | -0.0 points -1.0 to 0.9 | 1,277 | NCT05736874 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone) |
| Arm C - Fluticasone vs Arm C - Placebo: Number of Participants With Hospitalization, Urgent Care, Emergency Room Visit, or Death | 24 of 656 13 of 621 | 1.6 points -0.3 to 3.5 | 1,277 | NCT05736874 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone) |
| Arm C - Fluticasone vs Arm C - Placebo: serious adverse events | 3 of 656 7 of 621 | -0.7 points -1.9 to 0.4 | 1,277 | NCT05736874 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone) |
| Cervarix Group Without HPV-18 6-Month Persistent Infection vs Cervarix Group With HPV-18 6-Month Persistent Infection: Number of Seroconverted Subjects for Anti-HPV-18 Without and With 6-month Persistent Infection. | 1,242 of 1,248 28 of 28 | -0.5 points -1.0 to 11.6 | 1,276 | NCT00122681 Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 |
| Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Who Reporting Monitoring BP at Least 2 Times Per Week at Six Months Follow-up | 189 of 673 265 of 603 | -15.9 points -21.0 to -10.6 | 1,276 | NCT02996565 Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure |
Code
curl "https://conductscience.org/api/comparisons/v1?page=240"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=240
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT04308668-55245cee",
"title": "Treatment vs Placebo: Rate of Death",
"summary": "1 of 645 against 1 of 641; risk difference -0.0 points, 95% interval -0.7 to 0.7; NCT04308668, Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2",
"record": "/library/comparisons/NCT04308668-55245cee",
"nct_id": "NCT04308668",
"kind": "outcome",
"participants": 1286,
"risk_difference": {
"value": -0.000009674805596875113,
"lower": -0.007344873750816434,
"upper": 0.007283143480424106
},
"group_1": "1 of 645",
"group_2": "1 of 641",
"difference": "-0.0 points",
"interval": "-0.7 to 0.7",
"trial_title": "Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2"
},
{
"id": "NCT04308668-fe9f6202",
"title": "Treatment vs Placebo: Rate of Hospitalization",
"summary": "5 of 645 against 9 of 641; risk difference -0.6 points, 95% interval -1.9 to 0.6; NCT04308668, Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2",
"record": "/library/comparisons/NCT04308668-fe9f6202",
"nct_id": "NCT04308668",
"kind": "outcome",
"participants": 1286,
"risk_difference": {
"value": -0.006288623637968775,
"lower": -0.01948323432093614,
"upper": 0.00593490790352481
},
"group_1": "5 of 645",
"group_2": "9 of 641",
"difference": "-0.6 points",
"interval": "-1.9 to 0.6",
"trial_title": "Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=241",
"request_id": "rQtdokMDmwJ-ggJY"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant